The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
Clinical trial NCT07565285 · RECRUITING
Trial details
- NCT number
- NCT07565285
- Sponsor
- Primmune Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2027-12-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.